Have mutation, will travel: Utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology

Journal of Thoracic Oncology

Volumn 7, Issue 3, 2012, Pages 482-484

  West, Howard ^a,b   Camidge, D Ross ^c  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN;

CANCER PATIENT; CANCER SURVIVAL; CLINICAL RESEARCH; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC VARIABILITY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84857866866     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182432646     Document Type: Editorial

References (10)

1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
2. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2011;11:121-128.
3. Rosell R, Gervais, R, Vergnenegre A, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) paitents (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase II randomized trial. J Clin Oncol 2011;29(Suppl):Abstr 7503.
4. Zhao C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
5. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):Abstr 2501.
6. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009;4:1450-1454.
7. Weickhardt AJ, Camidge DR. The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence. Clin Invest 2011;1:1119-1126.
8. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29(Suppl):Abstr CRA7506.
9. Available at: http://cancergrace.org/lung/2010/02/26/dr-camidge-onesize- does-not-fit-all-alk-inhibition/; accessed October 19, 2011.
10. Butrynski JE, D'Adamo DR, Hornick JL. Crizotinib in ALK-rearranged inflammatory myelofibroblastic tumor. New Engl J Med 2010;363: 1727-1733.